Articles from February 2013

2013 RASCALS Foundation Events to Fight and End ALS!

Mark your calendars!
Join us for 2 fun and worthwhile events coming your way to help in the fight to end ALS!
RASCALS 4th Annual Trivia Night – September 7, 2013
Fight ALS One Step At A Time 5K Run/Walk – November 2, 2013
All proceeds help ALS Research and Family Assistance
Join us in making a difference this year!
Stay [...]

The RASCALS Foundation Announces Higher Education Scholarships for 2013

The RASCALS Foundation is pleased to announce that it is once again offering  the 2013 Higher Education Scholarship Program to assist families affected by ALS. We would like to acknowledge and thank our corporate partner, Walgreens, for their generous participation in making these important awards possible.
The scholarships will be available nationwide to the first 100 [...]

Western University Researchers Identify New Genetic Mutation for ALS

Strong’s team is convinced ALS is a disorder of RNA metabolism. RNA is the intermediary or messenger between genes and the protein being made. This new protein appears to play a critical role. “Every time we look at a cell degenerating, this particular protein was deposited abnormally in the cell. It was a common denominator,” explains Strong, who is also the Dean of Schulich Medicine & Dentistry. “Working with Dr. Rob Hegele at Robarts, we found there was a genetic mutation in the gene coding for this protein. So it’s a huge discovery.”

What Causes Lou Gehrig’s Sticky Masses?

Globs of protein clustered in the neurons that control muscles have long been the hallmark of amyotrophic lateral sclerosis (ALS), the fatal neurodegenerative disease also commonly known as Lou Gehrig’s disease. Now, a study of the most commonly found mutant gene in people with ALS reveals an unexpected origin of some of those sticky masses, a finding that may offer drug developers a new target for treatments.

Novel Protein May Help Detect Lou Gehrig’s Disease and Dementia, Mayo Clinic Finds

“This new finding sheds light on how the mutation causes these disorders, and it provides us with a marker that helps us track disease progression in patients with this disorder and potentially combat the disease,” says senior author Leonard Petrucelli, Ph.D., a molecular neuroscientist and director of the Department of Neuroscience at Mayo Clinic in Florida.